IP Verse

Hbv Antisense Inhibitors - EP2512491

The patent EP2512491 was granted to Glaxo Group on Oct 11, 2017. The application was originally filed on Oct 15, 2010 under application number EP10824199A. The patent is currently recorded with a legal status of "Revoked".

EP2512491

GLAXO GROUP
Application Number
EP10824199A
Filing Date
Oct 15, 2010
Status
Revoked
Apr 17, 2020
Grant Date
Oct 11, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ROCHEJul 10, 2018D YOUNG -

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2003148985
INTERNATIONAL-SEARCH-REPORTUS2005014712
INTERNATIONAL-SEARCH-REPORTUS2006128646
OPPOSITIONUS2003068301
OPPOSITIONUS2003139363
OPPOSITIONUS2003206887
OPPOSITIONUS2004054156
OPPOSITIONUS2007032441
OPPOSITIONUS2009137500
OPPOSITIONWO0116312
OPPOSITIONWO2012024170
OPPOSITIONWO2012145674
OPPOSITIONWO2015173208
OPPOSITIONWO9639502
OPPOSITIONWO9703211
SEARCHUS2003206887
SEARCHUS5985662
SEARCHWO2004078181

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "Chapter 19", CROOKE STANLEY T, Antisense Drug Technology, 2nd Ed., CRC PRESS, (20080000), pages 519 - 564, XP003036103
OPPOSITION- "Chapter 6", CROOKE, Antisense Drug Technology, 2nd Ed., CRC Press, pages 143 - 182, XP055461203
OPPOSITION- "Chapters 1 and 2", CROOKE Stanley T., Antisense Drug Technology, 2nd Ed., CRC Press, (20080000), pages 3 - 74, XP055501551
OPPOSITION- GRUNWELLER et al., "Locked Nucleic Acid Oligonucleotides", Biodrugs, (20070700), vol. 21, no. 4, pages 235 - 243, XP009125276
OPPOSITION- KOCH et al., "Quantum Mechanical Studies of DNA and LNA", Nucleic Acid Therapeutics, (20140100), vol. 24, no. 2, pages 139 - 148, XP055366884
OPPOSITION- REINIS et al., "INHIBITION OF HEPATITIS -B VIRUS SURFACE GENE EXPRESSION BY ANTISENSE OLIGODEOXYNUCLEOTIDES IN A HUMAN HEPATOMA CELL LIN.E ( hepatitis B virus/ PLC/PRF/5 cell line/ antisense oligonucleotides)", Folia Biologica, (19930512), vol. 39, no. 5, pages 262 - 269, XP000603123
OPPOSITION- S-H OH et al., "INHIBITION OF HEPATITIS B VIRUS EXPRESSION BY ANTISENSE OLIGODEOXYRIBONUCLEOTIDES", Korean Journal of Biochemistry, (19931200), vol. 25, no. 2, pages 113 - 118, XP000603311
OPPOSITION- HAGEDORN et al., "Locked nucleic acid: modality, diversity, and drug discovery", Drug Discovery Today, (20180100), vol. 23, no. 1, pages 101 - 114, XP055461215
OPPOSITION- VICKERS et al., "Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: A comparative analysis", J. Biol. Chem., (20030228), vol. 278, no. 9, pages 7108 - 7118, XP002281434
OPPOSITION- SWAYZE et al., "Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals", Nucleic Acid Res, (20070000), vol. 35, no. 2, pages 687 - 700, XP002539513

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents